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Simple approach to thieno[3,2-d]pyrimidines as new scaffolds
of antimicrobial activities
6¢-(4-Chlorophenyl)-spiro[cyclohexane-1,2 ¢-thieno[3,2-d][1,3]
oxazin]-4¢(1¢H)-one (1) was synthesized and used as a starting ma-
terial for the synthesis of a novel series of spiro compounds having 
biologically active sulfonamide 2a-e and 3¢-(4-acetylphenyl)-6¢-
(4-chlorophenyl)-1¢H-spiro[cyclohexane-1,2 ¢-thieno[3,2-d]
pyrimidine-4¢(3¢H)-one (3). Compound 2a was used as a key inter-
mediate for the synthesis of  sulfonyl carbothioamide derivatives 
4a-c. Also, compound 3 was used as an intermediate for the syn-
thesis of 3¢H-spiro[cyclohexane-1,2¢-thieno[3,2-d]pyrimidin]-3¢-yl]
phenyl}-2-imino-4-(substituted phenyl and/or thienyl)-1,2-dihy-
dropyridine-3-carbonitrile derivatives 5a-e, 3¢H-spiro[cy clo-
hexane - 1,2¢-thieno[3,2-d]pyrimidin]-3¢-yl]phenyl}-2-oxo-4-(substi-
tuted phenyl and/or thienyl)-1,2-dihydropyridine-3-car bonitrile 
derivatives 6a-e, and 4-[(2Z)-3-substituted-arylprop-2-enoyl]
phenyl-1¢H-spiro[cyclohexane-1,2¢-thieno[3,2-d]pyrimidine deriv-
atives 7a-e. Cyclocondensation of 7a-e with hydrazine hydrate 
produced 6¢-(4-chlorophenyl)-3¢-[4-(5-substituted aryl-4,5-dihy-
dro-1H-pyrazol-3-yl)phenyl]-1¢H-spiro[cyclohexane-1,2¢-thieno-
[3,2-d]pyrimidin]-4¢(3¢H)-ones 8a-e but with hydroxylamine hy-
drochloride afforded the corresponding isoxazoline derivatives 
9a-e. Also, cyclocondensation by thiourea afforded 2-thioxo-1,2-
dihydropyrimidin-4-yl)-phenyl-spiro-{cyclohexanethieno[3,2-d]
pyrimidin}-4-one derivatives 10a-e. The new compounds were 
investigated for antimicrobial activity. Compounds 2c, 8b,c, 9b 
and 10b were the most potent ones against both Gram-negative 
and Gram-positive bacteria. Compound 8c exhibited higher anti-
fungal activity towards the examined fungi with MIC of 1–2 µmol 
mL–1  compared to ketoconazole (MIC 2–3 µmol mL–1 ).
Keywords: thieno[3,2-d][1,3]oxazin]-4¢-one, thieno[3,2-d]pyrimidi-
nes, N-nucleophiles, spiro-thieno[3,2-d]pyrimidine, ring trans-
formation, antimicrobial 
Thienopyrimidines make an important class of heterocyclic compounds, which have 
attracted a great deal of attention due to their wide range of chemotherapeutic activities, 
including antimicrobial (1–4), moderate  activity against tumor cell proliferation in vitro 
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(5–7), antiviral (8, 9), analgesic and anti-inflammatory (10–13), antihistaminic (14) and an-
ticonvulsant  activities (15). With a variety of derivatives obtained by annulations and 
functional group manipulations, many thieno[3,2-d]-pyrimidine derivatives occupy a spe-
cial place because of their biological activities such as kinase (16–18) and  phosphodiester-
ase IV inhibiting (19, 20), gastric antisecretory (21) and antifolating (22) ones. Furthermore, 
several pyridone and imino pyridine derivatives are of chemotherapeutic importance (23).
The combinations of thieno[3,2-d]pyrimidines  with a variety of sulfa drugs and het-
erocycles might add a new biological, antibacterial and antifungal action. To the best of 
our knowledge, antibacterial and antifungal activity of thieno[3,2-d]pyrimidines has not 
been reported before.
EXPERIMENTAL
All melting points were taken on an Electrothermal IA 9100 series digital melting point 
apparatus (Shimadzu, Japan). Microanalytical data were obtained with the aid of a Vario 
Ele mentar Apparatus (Shimadzu). Elemental analyses of all compounds were within ± 0.4 % 
of the theoretical values (Table I). The IR spectra (KBr) were recorded on a Perkin-Elmer 
1650 spectrometer (Perkin-Elmer, USA). The 1H and 13C NMR spectra were measured with 
a Jeol ECA 500 MHz instrument (Jeol, Japan) in DMSO-d6 and chemical shifts were re-
corded in d ppm relative to TMS. Mass spectra (EI) were run at 70 eV with a Finnigan SSQ 
7000 spectrometer (Thermo-Instrument System Incorporation, USA).  Purity of the com-
pounds was checked on aluminium plates coated with silica gel (Merck, Germany). 
3-Amino-5-(4-chlorophenyl)-thiophene-2-carboxylic acid, p-amino-acetophenone, 
ciprofloxacin and ketoconazole were obtained from Sigma-Aldrich (USA).  Chemicals and 
solvents (Analar ≥ 99 %) were purchased from Sigma-Aldrich. 
Syntheses
6¢-(4-Chlorophenyl)-spiro[cyclohexane-1,2¢-thieno[3,2-d][1,3]oxazin]-4¢(1¢H)-one (1). – The 
compound was obtained from 3-amino-5-(4-chlorophenyl)thiophene-2-carboxylic acid 
(2.54 g, 0.01 mol) and cyclohexanone (1.24 g, 0.01 mol) refluxed in basic medium (ethanol 
and piperidine). The solid that separated upon cooling was filtered off in the form of white 
crystals.
Spiro[cyclohexane-1,2¢-thieno[3,2-d]pyrimidin]-3¢-yl]benzenesulfonamides (2a-e). General 
procedure. – A mixture of 1 (3.33 g, 0.01 mol) and 0.01 mol of the appropriate sulfa drug (sul-
fanilamide, sulfaguanidine, sulfadiazine, sulfapyridine, sulfamethoxazole) in 20 mL glacial 
acetic acid containing anhydrous sodium acetate (1.64 g, 0.02 mol) was refluxed for 20 h. 
Upon pouring on crushed ice/water, crystals were obtained, filtered, washed with water 
and recrystallized from a proper solvent to give 2a-e, respectively. The following com-
pounds were prepared: 4-[6¢-(4-chlorophenyl)-4¢-oxo-1¢,4¢-dihydro-3¢H-spiro[cyclohexane-
1,2¢-thieno[3,2-d]pyrimidin-3¢-yl]-benzenesulfonamide (2a), 3¢-(4-{[amino(imino)methyl]
sulfonyl}phe nyl)-6¢(4-chlorophenyl)-1¢H-spiro[cyclohexane-1,2¢-thieno[3,2-d]pyrimidin]-
4¢(3¢H)-one (2b), 4-[6¢- (4 -chloro-phenyl)-4¢-oxo-1¢,4¢-dihydro-3¢H-spiro[cyclohexane-1,2¢- 
thie no[3,2-d]pyrimidin]-3¢-yl]-N-pyrimidin-2-yl]-benzenesulfonamide (2c), 4-[6¢-(4-chlo ro-
phenyl)-4¢-oxo-1¢,4¢-dihydro-3¢H-spiro[cyclo hexane-1,2¢-thieno[3,2-d]pyrimi din]- 3¢- yl]- N - 









































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































4¢(3¢H)-one (3). – A mixture of 1 (3.33 g, 0.01 mol) and 4-aminoacetophenone (1.35 g, 0.01 mol) 
in glacial acetic acid (20 mL) was refluxed for 6 h in the presence of sodium acetate (1.64 g, 
0.02 mol). The reaction product was poured onto ice/water and neutralized with diluted 
NaOH. The obtained product was filtered off and washed with water to give pale yellow 
crystals.
N-({4-[6¢-(4-chlorophenyl)-4¢-oxo-1¢,4¢-dihydro-3¢H-spiro[cyclohexane-1,2 ¢-thieno[3,2-d]-
pyrimidin-3¢-yl]phenyl}sulfonyl) carbothioamide (4a-c). General procedure. – A mixture of 2a (2.44 g, 
0.05 mol) and anhydrous potassium carbonate (1.38 g, 0.01 mol) in dry acetone (50 mL) was 
refluxed under continuous stirring for 1.5 h. While hot, a solution of the appropriate isothio-
cyanate derivative, namely, methylisothiocyanate, cyclohexyl-isothiocyanate and phenyl 
isothiocyanate (0. 75 mol), in dry acetone was added dropwise and refluxing was continued 
for a further 18 h. Excess acetone was removed under reduced pressure and the obtained 
solid residue was washed with water, filtered and recrystallized from the proper solvent to 







ri midin]-3¢-yl]phenyl}-2-imino-4-aryl-1,2-dihydropyridine-3-carbonitriles (5a-e). General proce-
dure. – A mixture of acetyl derivative 3 (4.51 g, 0.01 mol), malononitrile (0.66 g, 0.01 mol) and 
the appropriate aldehyde (0.01 mol), and ammonium acetate (6.16 g, 0.08 mol) in n-bu ta nol 
(50 mL) was heated under reflux for 8 h. The solid that separated upon cooling was filtered 
off, washed with water and recrystallized from the proper solvent to obtain 5a-e, respecti vely. 
The following compounds were prepared: 6-{4-[6¢-(4-chlorophenyl)-4¢-oxo-1¢,4¢-dihydro-3¢H- 
spiro[cyclohexane-1,2¢-thieno[3,2-d]pyrimidin]-3¢-yl]phenyl}-2-imino-4-phenyl-1,2-dihy-
dropyridine-3-carbonitrile (5a), 4-(4-chlorophenyl)-6-{4-[6¢-(4-chlorophenyl)-4¢-oxo-1¢,4¢- 
dihydro-3¢H-spiro[cyclohexane-1,2¢-thieno[3,2-d]pyrimidin]-3¢-yl]phe nyl}-2-imino-1,2-di-




yl]-pyrimidin]-2-oxo-4-substituted aryl-1,2-dihydropyridine-3-carbonitriles (6a-e). General  pro-
cedure. – A mixture of acetyl derivative 3 (4.51 g, 0.01 mol), ethyl cyanoacetate (1.13 g, 0.01 
mol) and the appropriate aldehyde (0.01 mol), and ammonium acetate (6.16 g, 0.08 mol) in 
n-butanol (50 mL) was heated under reflux for 8 h. The solid that separated upon cooling 
was filtered off, washed with water, recrystallized from the proper solvent to give 6a-e, 
respectively. The following compounds were prepared: 6-{4-[6¢-(4-chlorophenyl)-4¢-oxo-
1¢,4¢-dihydro-3¢H-spiro[cyclohexane-1,2 ¢-thieno[3,2-d]pyrimidin]-3¢-yl]phenyl}-2-oxo-4-
phe nyl-1,2-dihydropyridine-3-carbonitrile (6a), 4-(4-chlorophenyl)-6-{4-[6¢-(4-chloro phe-
nyl)-4¢-oxo-1¢,4¢-dihydro-3¢H-spiro[cyclohexane-1,2¢-thieno[3,2-d]py ri midin]-3¢-yl]phenyl}-
2-oxo-1,2-dihydropyridine-3-carbonitrile (6b), 6-{4-[6¢-(4-chlorophenyl)-4¢-oxo-1¢,4¢-di hy-
dro-3¢H-spiro[cyclohexane-1,2¢-thieno[3,2-d]pyrimidin]-3¢-yl]phenyl}-4-(4-flurophenyl)-2-
341








6¢-(4-Clorophenyl)-3¢-{4-[(2Z)-3-substituted arylprop-2-enoyl]phenyl}-1¢H-spiro[cyclo hexa ne- 
1,2¢-thieno[3,2-d]pyrimidin]-4¢(3¢H)-ones (7a-e). General procedure. – A mixture of acetyl de-
rivative 3 (4.51 g, 0.01 mol) and the appropriate aldehyde (0.01 mol) in 5 % ethanolic sodium 
hydroxide solution (40 mL) was refluxed under stirring for 18 h. The reaction mixture was 
poured onto ice/cold water and neutralized with dil. HCl. The formed precipitate was fil-
tered off and recrystallized from the proper solvent to give 7a-e, respectively. The following 




phenyl}-1¢H-spiro[cyclohexane-1,2¢-thieno[3,2-d]pyrimidin]-4¢(3¢H)-one (7c), 6¢-(4- cloro phenyl) 
-3¢-(4-{(2Z)-3-[4-(dimethylamino)-phenyl]prop-2-enoyl]-phenyl}-1¢H-spiro-[cyclohexane-1,2¢-
thieno[3,2-d]pyrimidin]-4¢(3¢H)-one (7d), 6¢-(4-clo ro phenyl)-3¢-(4-[(2Z)-3-[2-(thienyl)prop-2-
enoyl]phenyl}-1¢H-spiro [cyclohexane-1,2¢-thieno[3,2-d]pyrimidin]-4¢(3¢H)-one (7e).
6¢-(4-Chlorophenyl)-3¢-[4-(5-substituted aryl-4,5-dihydro-1H-pyrazol-3-yl)phenyl]-1¢H-
spiro-[cyclohexane-1,2¢-thieno[3,2-d]pyrimidin]-4¢(3¢H)-ones (8a-e). General procedure. – A 
 mixture of unsaturated ketone 7a-e (0.01 mol) and 98 % hydrazine hydrate  in absolute 
ethanol (2 mL) was refluxed for 6 h. Upon cooling, white crystals were obtained, filtered 
off and recrystallized from the proper solvent to obtain 8a-e, respectively. The following 
compounds were prepared: 6¢-(4-chlorophenyl)-3¢-[4-(5-phenyl-4,5-dihydro-1H-pyrazol-
3yl)phenyl]-1¢H-spiro[cyclohexane-1,2¢-thieno[3,2-d]-pyrimidin]-4¢(3¢H)-one (8a), 6¢- (4-chloro 
phenyl)-3¢-{4-(5-(4-chlorophenyl)-4,5-dihydro-1H-pyrazol-3yl)phenyl]-1¢H-spi ro[cy clo-







clohexane-1,2¢-thieno[3,2-d]pyrimidin]-4¢(3¢H)-ones (9a-e). General procedure. – A mixture of 
unsaturated ketone 7a-e (0.01 mol) and hydroxylamine hydrochloride (1.38 g, 0.02 mol) in 
sodium hydroxide solution (0.5 g NaOH in 0.5 mL water) in ethanol (60 mL) was refluxed 
for 3 h. The product obtained upon cooling was filtered off, washed with water and recrys-
tallized from the proper solvent to obtain the desired 9a-e, respectively. The following 
compounds were prepared: 6¢-(4-chlorophenyl)-3¢-[4-(5-phenyl-4,5-dihydroisoxazol-3-yl)











































2 a R = H
b R = C(NH)NH2
c R =










1¢H-spiro[cyclohexane-1,2¢-thieno-[3,2-d]pyrimidin]-4¢(3¢H)-ones (10a-e). General procedure. – A 
mixture of unsaturated ketone 7a-e (0.01 mol), thiourea (0.01 mol) and sodium hydroxide 
(0.1 g) in absolute ethanol (30 mL) was refluxed for 6 h. The reaction mixture was concen-
trated under vacuum, cooled and neutralized with dilute HCl. The formed product was 












Antimicrobial activity. – Antimicrobial activity of the newly synthesized compounds was 
tested in vitro against the following bacteria: Gram-negative bacteria Escherichia coli (ATCC 
23556), Klebsiella pneumoniae (ATCC 27853) and Pseudomonas aeruginosa (ATCC 10145), Gram- 
Scheme 1
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a  R = CH3
b  R = cyclohexyl
























a Ar = C6H5
b  Ar = 4-ClC6H4
c Ar = 4-FC6H4
d  Ar = 4-N(CH3)2C6H4









a Ar = C6H5
b  Ar = 4-ClC6H4
c Ar = 4-FC6H4
d  Ar = 4-N(CH3)2C6H4









a Ar = C6H5
b Ar = 4-ClC6H4
c Ar = 4-FC6H4
d Ar = 4-N(CH3)2C6H4















-positive bacteria Streptococcus lactis (ATCC 6523), Staphylococcus aureus (ATCC 25923), Entero-
coccus faecalis (ATCC 5787) and the fungi Candida albicans (ATCC 15056), Aspergillus flavus 
(ATCC-24556) and Ganoderma lucidum (ATCC-96918). All microorganisms were purchased 
from the American Type Culture Collection (Manassas, VA, USA). The newly synthesized 
344










a Ar = C6H5
b  Ar = 4-ClC6H4
c Ar = 4-FC6H4
d  Ar = 4-N(CH3)2C6H4






























8, 9, 10 a  Ar = C6H5
               b  Ar = 4-ClC6H4
               c  Ar = 4-FC6H4
               d  Ar = 4-N(CH3)2C6H4









compounds were dissolved in dimethylsulfoxide (DMSO) and tested for antimicrobial activ-
ity by the agar disk diffusion technique (24), taking ciprofloxacin (25) and ketoconazole (26) 
as reference drugs for bacteria and fungi, respectively. A solution of 100 µg  mL–1 of the test 
compound was applied and microplate-wells, 1 cm in diameter, were used. Zones of inhibi-
tion were measured with calipers or automated scanners and were compared with those of 
the standards. Ciprofloxacin (0.15 µmol mL–1) and ketoconazole (0.037 µmol mL–1) were used 
as reference drugs for antibacterial and antifungal activity, respectively. Compound-im-
pregnated disks were placed on an agar plate containing a standard suspension of microor-
ganisms. The plate was incubated for 24 h at 37 °C.   
For evaluation of minimum inhibitory concentration (MIC) by the serial plate dilution 
method (27), 5 mg of each test compounds were dissolved in 1 mL of DMSO separately to 
prepare stock solutions. Serial dilutions were prepared from each stock solution. The 
plates were incubated at 37 °C for 24 h. MIC is defined as the lowest concentration (µmol 
mL–1) of the test compound that results in no visible growth on the plates. DMSO was used 
as a solvent control to ensure that the solvent had no effect on bacterial growth. The results 
are summarized in Tables III and IV.
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The first step of our strategy was focused on ring transformation of oxazin to 
thieno[3,2-d]pyrimidine (28, 29). Treatment of 3-amino-5-(4-chlorophenyl)thiophene-2-
carboxylic acid with cyclohexanone yielded 6¢-(4-chlorophenyl)-spiro-[cyclohexane-1,2¢-
thieno[3,2-d][1,3]-oxazin]-4¢(1¢H)-one  (1)  in good yield (Scheme 1). 
Transformation of oxazine derivative ring into N-substituted aryl sulfonamide de-
rivative was carried out through the treatment of 1,3-oxazine (i. e., thieno[3,2-d][1,3]oxazin- 
-4-one, 1) with sulfa drug, namely, sulfanilamide, sulfaguanidine, sulfadiazine, sulfapyri-
dine or sulfamethoxazole,  in refluxing glacial acetic acid and  in the presence of anhydrous 
sodium acetate, yielding the title compounds 2a-e in a moderate yield. 
Variation of different aryl or heterocyclic moieties in 2/3 position of thieno[3,2-d]-[1,3]
oxazin-4-one  (1) may influence the pharamacological action. Herein, we explore the influ-
ence of aryl or heteroaryl moieties in N2 of pyrimidine nucleus. 1,3-Oxazine (1) was al-
lowed to condense with p-amino-acetophenone  in glacial acetic acid in the presence of 
anhydrous sodium acetate to give the corresponding key intermediate, thieno[3,2-d]-py-
rimidin-one (3) in a good yield (Scheme 1). 
Free amino groups of sulfonyl derivatives 2a reacted with methyl isothiocyanate de-
rivatives in dry acetone and anhydrous potassium carbonate, affording thiourea deriva-
tives 4a-c (Scheme 2). Besides correct values of elemental analyses, IR, NMR and mass 
spectra of compounds 4a-c are in agreement with the assigned structures (Tables I, II). IR 
spectrum of 4a shows C=O at d 1680 cm–1 and broad absorption bands at d 3340 and 3325 
cm–1 for three NH, respectively. 1H NMR spectra showed singlet CH3 at δ 2.19 ppm, multi-
plet signals for 5 CH 2 at δ 2.41 to 3.02 ppm, singlet signal for the thiophene proton at δ 7.43 
ppm and four duplet signals at δ 6.98–7.05 (d, 2H, J = 8.5 Hz, Ar-H), δ 7.28–7.31 (d, 2H, J = 8.2 
Hz, Ar-H), δ 7.62 (d, 2H, J = 8.0 Hz, Ar-H), δ 7.85 ppm (d, 2H, J = 8.0 Hz, Ar-H) for two 4-sub-
stituted phenyls. Moreover, broad absorption signals for three NH groups at δ 9.52–10.35 
ppm were observed, respectively. The mass spectra of all compounds showed correspond-
ing molecular ion (M+) in addition to characteristic fragmentation peaks. Chloro-substitut-
ed compounds displayed M+2 peaks in addition to the  molecular ion peaks (M+).
Refluxing compound 3 with the appropriate aldehyde and  malononitrile or ethyl 
cyanoacetate in the presence of excess ammonium acetate in n-butanol afforded the cor-
responding aminopyridine 5a-e and pyridone derivatives 6a-e, respectively. Also, treat-
ment of acetyl derivative 3 with appropriate aldehydes in 5 % ethanolic sodium hydroxide 
solution, afforded the corresponding α,β-unsaturated ketones 7a-e in moderate yields 
(Scheme 3). The 1H NMR spectra of compounds 5, 6 and 7 revealed absorption bands of 
five (CH2–) methylene groups as multiplet absorption signals of the cyclohexane ring 
around d 2.46–3.01 ppm (Table II).
α,β-unsaturated ketone is a simple substrate to synthesize a variety of heterocycles of 
known biological interest. Cyclocondensation of compounds 7a-e with N-nucleophiles un-
der appropriate experimental conditions afforded pyrazoline derivatives 8a-e, isoxazo-
lines 9a-e and  thiopyrimidine derivatives 10a-e (Scheme 4).  
Postulated structures of the newly synthesized compounds 8, 9 and 10 are in agree-
ment with their IR, NMR spectral and elemental analysis data (Tables I, II). The 1H  NMR 
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Table III. Minimal inhibitory concentration of the synthesized compounds against bacteria
Compd.
MIC (mmol L–1)













1 8 8 7 6 5 8
2a 5 3 5 4 4 5
2b 6 4 7 3 4 5
2c 3 3 2 2 1 2
2d 6 6 7 3 3 4
2e 2 3 2 2 2 4
3 7 7 5 5 4 7
4a 6 5 5 5 4 6
4b 6 5 5 5 5 7
4c 7 6 6 5 4 5
5a 7 6 7 4 5 6
5b 4 4 4 1 2 3
5c 4 3 3 2 2 4
5d 6 7 7 5 4 6
5e 8 6 7 4 4 7
6a 9 7 6 5 5 7
6b 8 7 6 5 7 6
6c 6 9 7 5 4 6
6d 7 8 6 6 6 7
6e 8 9 6 8 7 9
7a 7 8 7 8 6 8
7b 9 8 9 6 7 9
7c 7 9 7 8 8 9
7d 8 6 8 - 10 -
7e 9 8 8 6 6 7
8a 8 9 7 5 6 6
8b 3 2 3 2 1 2
8c 2 3 4 1 1 2
8d 9 7 7 5 6 8
8e 6 6 5 4 5 5
9a 10 7 7 5 5 7
9b 4 4 3 2 1 3
9c 3 3 2 3 2 4
9d 8 7 6 6 5 7
9e 7 6 5 5 4 5
10a 7 8 8 5 5 7
10b 2 1 4 1 2 3
10c 4 2 2 2 3 3
10d 9 8 7 4 7 7
10e 6 6 5 3 2 5
Negative 
control NI NI NI NI NI NI
Cipro-
floxacin 5 4 4 2 2 4
DMSO is a negative control; also the solvent for test compounds and the reference drug. 
NI – No inhibition
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Table IV.  Minimal inhibitory concentration of the synthesized compounds against fungi
Compd.
MIC (µmol mL–1)
Candida albicans              Aspergillus flavus Ganoderma lucidum
1 7 6 5
2a 10 12 11
2b 13 11 10
2c 11 12 12
2d 13 - -
2e 12 10 10
3 7 6 7
4a - 16 -
4b 14 12 12
4c 11 10 12
5a 7 7 6
5b 6 7 6
5c 6 6 7
5d 8 6 7
5e 8 11 10
6a 9 9 8
6b 9 8 10
6c 7 8 8
6d - 10 -
6e 8 9 9
7a 7 6 8
7b 8 8 7
7c 8 6 7
7d 6 7 6
7e 6 8 7
8a 5 5 6
8b 4 5 4
8c 2 2 1
8d 7 6 6
8e 3 2 2
9a 7 4 6
9b 6 6 8
9c 6 5 7
9d 8 6 6
9e 6 5 7
10a 8 6 6
10b 5 4 4
10c 4 3 3
10d 7 6 7
10e 4 4 5
Negative control NI NI NI
Ketoconazole 3 2 3
DMSO is a negative control, also the solvent for test compounds and the reference drug. 
NI – No inhibition
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spectrum of 8c, for example, showed multiple signals at d 2.16 to 3.01 ppm corresponding 
to the six methylene groups and a multiple signal corresponding to the pyrazole proton at 
d 3.42 ppm. It also showed the aromatic protons at d 6.94–7.01 (d, 2H, J = 8.3 Hz, Ar-H), 
7.11–7.15 (d, 2H, J = 8.2 Hz, Ar-H), 7.20–7.28 (d, 2H, J = 8.0 Hz, Ar-H), 7.41 (s, 1H thiophene 
ring), 7.53–7.60 (d, 2H, J = 8.0 Hz, Ar-H), 7.67–7.72 (d, 2H, J = 8.1 Hz, Ar-H), 7.82–7.86 ppm (d, 
2H,  J = 7.9 Hz, Ar-H), and finally two broad bands corresponding to 2 NH at d 9.15 and 
10.25 ppm which were D2O exchangeable.
Antimicrobial screening and SAR
Preliminary antimicrobial screening was carried out for all newly synthesized com-
pounds and the results are summarized in Tables III and IV. Many of the test compounds dis-
played good antimicrobial activity, comparable to that of ciprofloxacin (MIC = 2–5 µmol mL–1). 
Compounds 2c, 8b,c, 9b and 10b were the most potent ones against both Gram-negative and 
Gram-positive bacteria with MIC values ranging from 1 to 4 µmol mL–1. Antibacterial activ-
ity of these compounds may result from the basic skeleton of the molecules. In addition, the 
presence of substituent in the phenyl ring attached to thieno[3,2-d]pyrimidine such as N-
pyrimidinyl benzenesulfonamide in 2c, 4-chloro and 4-fluorophenylpyrazolyl in 8b,c, 
4-chlorophenyl isoxazole in 9b and 4-chlorophenyl thioxopyrimidinyl in 10b should be 
taken into account. Compounds 2e, 9c and 10c were found to be more potent against Gram-
negative bacteria with MIC of 2–4 µmol mL–1 and equipotent against Gram-positive bacteria 
compared to ciprofloxacin. Their activity is attributed to the presence of methyl oxazole 
benzenesulfonamide in 2e, 4-fluorophenyl isoxazole in 9c and 4-fluorophenyl thioxopyrim-
idinyl in 10c, which are attached to the phenyl ring of the basic skeleton.
On the other hand, compound 5b showed slightly higher to comparable antimicro-
bial activity to that of the standard drug against Gram-positive bacteria and equipotent 
against Gram-negative bacteria, while compound 5c showed slightly higher activity 
against Gram-negative bacteria, but was equipotent against Gram-positive bacteria. 
These activities may be due to the presence of 4-chlorophenyl-pyridinyl in 5b and 4-flu-
orophenyl-pyridinyl in 5c. Also, compounds 5a,d,e exhibited moderate activities com-
pared to ciprofloxacin. Compounds with methyl, like in 4a, cyclohexyl in 4b and phenyl-
sulfonylthioamide in 4c, as well as the compounds bearing amino(imino)methylsulfonyl 
moiety, like in 2b, and N-pyridinyl-benzenesulfonamide in 2d display good antibacterial 
activity.
Compounds 8e, 9e, 10e exhibited good activities still lower than ciprofloxacin. These 
compounds are of high molecular mass and bearing a bulky substituent (thienyl group) at 
nitrogen in position 3 in the thieno[3,2-d]pyrimidine moiety. In addition, the presence of 
heteroatoms such as oxygen, sulfur and nitrogen plays a vital role in the observed antibac-
terial activity. The electronic nature of the substituent on the side-chain phenyl is an im-
portant factor in determining inhibitory potency. Thus, compounds without substituents 
in the phenyl group attached to the pyrazolyl in 8a, isooxazolyl in 9a and thioxopyrimidnyl 
in 10a,  or phenyl with an electron donating group [N(CH3)2] as in compounds  8d, 9d and 
10d exhibited moderate activities. Compounds 3, 6a-e, 7a-c and 7e displayed moderate 
activity, while compound 7d exhibited moderate activity against Gram-negative bacteria 
but not against Gram-positive bacteria. Compound 6¢-(4-chlorophenyl)-spiro[cyclohexane-
1,2¢-thieno[3,2-d][1,3]oxazin]-4¢(1¢H)-one (1) exhibited moderate antibacterial activity com-
pared to ciprofloxacin.
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On the other hand, compound 8c exhibited higher antifungal activity with MIC of 1-2 
µmol mL–1 than ketoconazole (MIC 2–3 µmol mL–1), while compounds 8a,b and 10b,c,e 
were nearly as active as ketoconazole. Furthermore, most of the synthesized compounds, 
namely,  1, 5a-d, 6a-c, 6e, 7a-e, 8d, 9a-e, 10a and 10d, exhibited moderate antifungal activ-
ity. Compounds with benzene sulfonamides showed low antifungal activity (2a-e, 4b,c 
and 5e), or were devoid of  antifungal activity (2d and 4a, 5e).
CONCLUSIONS
Many among of the differently substituted 4-[6¢-(4-chlorophenyl)-4¢-oxo-1¢,4¢-dihydro-
3¢H-spiro[cyclohexane-1,2¢-thieno[3,2-d]pyrimidinyl derivatives exhibit antimicrobial ac-
tivity higher than the standard drug ciprofloxacin. Particularly, spirocyclohexane-1,2¢-
thieno[3,2-d]pyrimidinyl with the substituent in the phenyl ring attached to thieno[3,2-d]
pyrimidine, such as N-pyrimidinyl in 2c, N-(2-methyloxazolyl) benzenesulfonamide in 2e, 
4-chloro and 4-fluorophenylpyrazolyl in 8b,c, 4-chlorophenyl isoxazole in 9b and 4-chlo-
rophenyl thioxopyrimidinyl in 10b, showed high activity. Derivatives with 4-chlorophenyl 
in 5b, 4-fluorophenyl in 5c, methyl in 4a, cyclohexyl in 4b and phenyl sulfonylthioamide 
in 4c showed good antibacterial activity. Compound 8c exhibited higher antifungal activ-
ity than ketoconazole. Compounds with electron withdrawing substitutents on the phenyl 
ring were more potent than their analogues with electron donating substituents or with 
unsubstituted phenyl.
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